Checkpoint - Globe Thesis

Keyword [Checkpoint] Result: 181 - 200 \| Page: 10 of 10
181.	Expression And Clinical Significance Of Negative Immune Checkpoint Regulator VISTA In Hepatocellular Carcinoma
182.	Efficacy Of PD-1/PD-L1 Immune Checkpoint Inhibitors For Advanced Nsclc According To PD-L1 Expression: A Meta-analysis
183.	Mechanism Of Targeted Regulation Of Mps1 On Proliferation,Apoptosis And Metastasis Of OS Cells
184.	Clinical Pathological Characteristics Of Liver Injury Associated With Immune Checkpoint Inhibitors
185.	The Role Of Immunotherapy In Advanced Non-Small Cell Lung Cancer With Driver Gene Mutations
186.	The Expression And Clinical Significance Of B7-H3 And CTLA-4 In Non-small Cell Lung Cancer
187.	The Expression Of PD-L1 And Its Relationship With Prognosis In Different Subtypes Of Esophageal Cancer
188.	Mechanism Of Cell Cycle Checkpoint Kinase 2 Phosphorylation Modified DNTP Hydrolase SAMHD1 To Regulate DNA Damage Repair
189.	Preparation And Function Of TIM-3 Single Domain Antibody
190.	Anti-CD47 Blockade Synergizes With Chemo-photothermal Therapy For Enhanced Tumor Immunotherapy
191.	Study On Prognosis Of Small Cell Lung Cancer Based On Tumor Immune Microenvironment
192.	Distant Metastasis Patterns And Abscopal Effects Of Non-small Cell Lung Cancer
193.	Indirect Comparison Between Immune Checkpoint Inhibitors And Immune Checkpoint Inhibitors Plus Chemotherapy As First-line Treatment For Advanced Non-small Cell Lung Cancer:A Systematic Review
194.	Effects Of Liver-targeted Drugs On Expression Of Immune-related Proteins In Hepatocellular Carcinoma Cells
195.	M1-like Macrophages Supernatant Induced High Expression Of Immune Checkpoint Molecules In Hepatocellular Carcinoma Cells
196.	Anti-tumor Activity Of Anti-PD-1 Antibody In Lewis Lung Carcinoma Mouse Model
197.	The Preparation And Evaluation Of Tumor Associated Antigen Polypeptide Loaded Poly (β-amino Ester) Nano-Vaccines
198.	Biomaterials For Innovative Combinational Cancer Immunotherapy
199.	MiRNA-968 Targets Expanded In HIPPO Signaling Pathway To Regulate DNA Damage
200.	Risk Of Immune-Related Adverse Events Associated With Ipilimumab-Plus-Nivolumab And Nivolumab Therapy In Cancer Patients
<<First <Prev Next> Last>> Jump to